Glycomics focuses on the structures and functions of complex carbohydrates, as found in glycoproteins, glycolipids, and glycosaminoglycans. Glycans are responsible for much of the structural variation in biologic systems, and their representation on cell surfaces is commonly called the “glycome”. These glycans are present in many areas of the microbiome, including cell surfaces and proteins, and can be incredibly complex. Microbial glycomics is poised to revolutionize disease diagnosis, cancer detection, personalized medicine, antimicrobial vaccine, and drug discovery. As therapeutic agents, glycan-integrated nanomaterials can be used as a vaccine against viral and bacterial infections and cancer cells.
Genzyme Corporation and GlaxoSmithKline plc.- Notable Market Players in Glycomic Therapeutics Market
The glycomic therapeutics market majorly consists of the players such as Intellihep Ltd; Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Halozyme Therapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. The companies have been implementing various strategies that have helped the growth of the company and in turn, have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgrades for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the glycomic therapeutics market:
| Year | News |
| Aug-2022 | Sanofi announced that it has entered into a strategic collaboration with Innovent Biologics. The collaboration aims to accelerate the development of oncology medicines and expand its presence in China. |
| May-2022 | Halozyme Therapeutics announced the completion of its acquisition of Antares Pharma, Inc. The acquisition aims to create specialty products. |
| June-2022 | GSK plc announced an investment of £1bn over ten years to accelerate R&D dedicated to infectious diseases that disproportionately impact lower-income countries. This research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR). |
| March-2022 | Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A. announced final results from the BRIGHT Phase III clinical trial evaluating pegunigalsidase alfa (PRX-102) for the potential treatment of Fabry disease. The results indicate that treatment with 2 mg/kg of PRX-102 administered by intravenous (IV) infusion every four weeks was well tolerated. |
